Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M BARR

Showing results (831-840 of 848) with videos related to

Pageof 85
Sort By:
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
JAMA|December 15, 2020
Association Between Depressive Symptoms and Incident Cardiovascular DiseasesEric L Harshfield, Lisa Pennells, Joseph E Schwartz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 21, 2013
Guidelines on the use of extracorporeal photopheresisR Knobler, G Berlin, P Calzavara-Pinton, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.
Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.
Pageof 85

Showing results (831-840 of 848) with videos related to

Sort By:
Pageof 85
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
JAMA|December 15, 2020
Association Between Depressive Symptoms and Incident Cardiovascular DiseasesEric L Harshfield, Lisa Pennells, Joseph E Schwartz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 21, 2013
Guidelines on the use of extracorporeal photopheresisR Knobler, G Berlin, P Calzavara-Pinton, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.
Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.
Pageof 85